Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Gunn Justin Frederick 2. Date of Event Requiring Statement (Month/Day/Year) 10/01/2026 3. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT] (Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) See Remarks 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) REDWOOD CITY, CA 94065 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 12,191(1)(2) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	(3)	08/01/2034	Common Stock	25,000	$37.94	D
Stock option (right to buy)	(4)	02/28/2035	Common Stock	25,000	$60.58	D
Stock option (right to buy)	(5)	02/27/2036	Common Stock	13,438	$35.7	D
Stock option (right to buy)	(6)	02/27/2036	Common Stock	8,959	$35.7	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Gunn Justin Frederick C/O CORCEPT THERAPEUTICS INCORPORATED 101 REDWOOD SHORES PARKWAY REDWOOD CITY, CA 94065			See Remarks

Signatures

By: /s/ Joseph Douglas Lyon, as attorney-in-fact for Justin Gunn		10/05/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Includes 141 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 316 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 405 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 103 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
(2)	Includes 6,000 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. The shares underlying the restricted stock unit will vest in equal installments on each quarterly anniversary of September 1, 2026 over a four-year period provided the Reporting Person satisfies certain requirements.
(3)	There were originally 50,000 shares subject to the stock option and an aggregate of 25,000 shares have been previously exercised. The shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on August 1, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on August 1, 2028, subject to the Reporting Person's continued service.
(4)	Exercisable ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.
(5)	There were originally 15,000 shares subject to the stock option and an aggregate of 1,562 shares have been previously exercised. The shares subject to the stock option vested and became exercisable ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.
(6)	There were originally 10,000 shares subject to the stock option and an aggregate of 1,041 shares have been previously exercised. The shares subject to the stock option vested and became exercisable ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.
Remarks: President, Corcept Endocrinology Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.